Fdc Sales Mis May 2026

The drug was called Nebuflam-D . A fixed-dose combination of an expectorant, a low-dose steroid, and a novel mucolytic. It was supposed to be a blockbuster for chronic bronchitis. The clinical trials were solid. The pricing was aggressive. The sales force was incentivized to the teeth.

On days when the company ran high-intensity sales blitzes, primary sales spiked—but redemption data showed no corresponding increase . In fact, on those days, the system recorded a suspiciously high number of prescriptions written after 9 PM , which was impossible because most clinics closed by 7.

Someone was entering fake prescriptions into the system to game the CRM. Fdc Sales Mis

Pooja hesitated. Then she opened a drawer. Inside were forty sheets of blank prescription pads—with Dr. Iyengar’s forged stamp.

And yet, week four of the launch, the MIS dashboard showed a flat green line where a hockey stick should have been. The drug was called Nebuflam-D

Arjun picked up his phone and called the rep. “Rajesh, Dr. Iyengar—did she prescribe Nebuflam-D in week one?”

Arjun stared at the glowing screen in his cubicle at 9:47 PM. The office was empty except for the janitor, who hummed an old Hindi film tune while mopping the corridor. On Arjun’s monitor, a cascade of numbers scrolled silently: units sold, doctor prescriptions, stockist balances, tertiary sales, secondary sales, primary sales. The clinical trials were solid

He walked out of the data entry room, past the janitor who had stopped humming, past the empty cubicles, past the motivational posters that said “Data is the new science.”